Latest Peptides Stories
BASKING RIDGE, N.J., April 9 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven Zelenkofske, DO, FACC, Senior Vice President, Chief Medical Officer, presented an abstract at the Arteriosclerosis, Thrombosis and Vascular Biology Scientific Sessions on April 9, 2010 at 5pm (PST) in San Francisco, CA.
New Peptide Array Facility Designed to Expedite the Drug Discovery Process VANCOUVER, March 16 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced the launch of a new peptide synthesis facility to provide researchers with the latest in peptide array technologies.
BASKING RIDGE, N.J., March 15 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.
ST. LOUIS, Feb. 25 /PRNewswire/ -- Supelco, a division of Sigma-AldrichÂ® (Nasdaq: SIAL), announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core(TM) particle design.
The search for new therapeutic agents is time-consuming and expensive.
NEW YORK, Feb. 11 /PRNewswire/ -- A clinical study by Dr. Jay Hoffman, PhD, professor and chair of the Department of Health and Exercise Science at the College of New Jersey, has shown Sustamine(TM) L-Alanyl-L-Glutamine, increases performance in endurance exercise and activity.
SALEM, N.H., Jan. 26 /PRNewswire/ -- ALPCO Diagnostics has developed two new low-sample volume ELISAs for the quantitative analysis of total proinsulin (I and II) in rats and mice.
A strip of paper infused with carbon nanotubes can quickly and inexpensively detect a toxin produced by algae in drinking water.
BASKING RIDGE, N.J., Dec. 17 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.
Approximately 20 percent of dialysis patients undergoing a percutaneous coronary intervention (PCI; procedure such as angioplasty) are given an antithrombotic medication they should not receive, which may increase their risk for in-hospital bleeding.